SIONSionna Therapeutics, Inc.
$51.04+193% 1Y
$51.04
$4.5052 weeks$51.04
SION as reported
- Net income
- −$97M
Net income · +28% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$76M
Free cash flow · +19% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.17
EPS · −100% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$97M | +28% | Q2 2026 |
| EPS | −$2.17 | −100% | Q2 2026 |
| ROE | −28% | n/a | Q2 2026 |
| ROA | −27% | n/a | Q2 2026 |
| Free cash flow | −$76M | +19% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Sionna Therapeutics, Inc. (SION) · Net incomeNet incomeSionna Therapeutics, Inc. (SION)
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry